Comment: Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient

Gary MM , Harrison DJ . Analysisof severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother 2006; 40: 191–7. Epub 27 Dec 2005. DOI 10.1345/aph.1G481

Henderson JT , Hwang AC , Harper CC , Stewart FH . Safety of mifepristone abortions in clinical use. Contraception 2005;72:175–8.

Grimes DA . Estimation of pregnancy-repeated mortality risk by pregnancy outcome, United States, 1991–1999. Am J Obstet Gynecol 2006;194:92–4.

Food and Drug Administration. Mifepristone questions and answers, 4/17/02. www.fda.gov/cder/drug/infopage/mifepristone/mifepristone-qa_4_17_02.htm#2 (accessed 2006 Jan 11).

Medwatch Adverse Event Reports. Individual Safety Report no. 3943786–2. Rockville, MD: Office of Postmarketing Drug Risk Assessment, Food and Drug Administration.